Should I buy or sell Genprex stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNPX shares. View GNPX analyst ratings or view top-rated stocks .

What is Genprex's stock price target for 2024?

1 brokerages have issued 1-year target prices for Genprex's shares. Their GNPX share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 352.5% from the stock's current price. View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts .

How have GNPX shares performed in 2024?

Genprex's stock was trading at $9.20 at the start of the year. Since then, GNPX stock has decreased by 76.0% and is now trading at $2.21. View the best growth stocks for 2024 here .

Are investors shorting Genprex?

Genprex saw a decrease in short interest in March. As of March 31st, there was short interest totaling 70,000 shares, a decrease of 12.8% from the March 15th total of 80,300 shares. Based on an average daily trading volume, of 83,200 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.8% of the shares of the stock are sold short. View Genprex's Short Interest .

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our GNPX earnings forecast .

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) released its quarterly earnings results on Monday, April, 1st. The company reported ($9.20) earnings per share for the quarter, missing analysts' consensus estimates of ($5.40) by $3.80.

When did Genprex's stock split?

Genprex shares reverse split on Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Vaxart (VXRT) , Tonix Pharmaceuticals (TNXP) , Co-Diagnostics (CODX) , OPKO Health (OPK) , SCYNEXIS (SCYX) , iBio (IBIO) and Advanced Micro Devices (AMD) .

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GNPX

Genprex (GNPX) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free GNPX Stock Alerts

$2.21

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.18
▼
$2.27
50-Day Range: $2.21
▼
$4.90
52-Week Range: $2.18
▼
$45.20

Volume: 17,491 shs
Average Volume: 74,687 shs
Market Capitalization: $4.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Genprex alerts:

Genprex MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 352.5% Upside
$10.00 Price Target
Short Interest: Healthy
3.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.77) to ($2.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.19 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Genprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Genprex has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.78% of the float of Genprex has been sold short.
Short Interest Ratio / Days to Cover
Genprex has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Genprex has recently decreased by 12.83%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Genprex does not currently pay a dividend.
Dividend Growth
Genprex does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Genprex has received a 75.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Genprex is -0.78.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
4 people have added Genprex to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genprex insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.54% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.05% of the stock of Genprex is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Genprex are expected to grow in the coming year, from ($5.77) to ($2.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Genprex is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genprex is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Genprex has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Genprex Stock (NASDAQ:GNPX)

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNPX Stock News Headlines

April 9, 2024 | finance.yahoo.com

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

April 9, 2024 | prnewswire.com

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 3, 2024 | markets.businessinsider.com

Genprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock Up

April 3, 2024 | prnewswire.com

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

April 2, 2024 | markets.businessinsider.com

Genprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy

April 2, 2024 | prnewswire.com

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

March 22, 2024 | prnewswire.com

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 21, 2024 | marketwatch.com

Genprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8M

March 20, 2024 | marketwatch.com

Genprex Shares Hit 52-Week Low After Direct Offering Prices

March 19, 2024 | prnewswire.com

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 19, 2024 | finanznachrichten.de

Genprex, Inc.: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 19, 2024 | prnewswire.com

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 12, 2024 | markets.businessinsider.com

Genprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 Antibodies

March 12, 2024 | finance.yahoo.com

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

March 9, 2024 | theglobeandmail.com

Genprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual Meeting

March 6, 2024 | prnewswire.com

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

February 26, 2024 | theglobeandmail.com

Genprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor Conference

February 7, 2024 | markets.businessinsider.com

Genprex To Expand Non-clinical Program To Study TUSC2, NPRL2

February 7, 2024 | finance.yahoo.com

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

February 6, 2024 | marketwatch.com

Genprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso Trial

February 6, 2024 | msn.com

Genprex Launches Phase 2a Reqorsa Trial Expansion

February 6, 2024 | finance.yahoo.com

Genprex to Present at Upcoming BIO CEO & Investor Conference

February 5, 2024 | finance.yahoo.com

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

January 31, 2024 | msn.com

Dow Turns Lower; Federal Reserve Keeps Rates Unchanged

January 31, 2024 | msn.com

Genprex to effect 1-for-40 reverse stock split to regain Nasdaq compliance

See More Headlines

Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/01/2019
Today: 4/18/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GNPX
CUSIP: N/A
CIK: 1595248
Web: www.genprex.com
Phone: (877) 774-4679
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +352.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($24.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -245.62%
Return on Assets: -185.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.31
Quick Ratio: 2.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.99 per share
Price / Book: 0.44

Miscellaneous

Outstanding Shares: 1,910,000
Free Float: 1,690,000
Market Cap: $4.22 million
Optionable: Optionable
Beta: -0.61

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. John Rodney Varner (Age 67)
Co-Founder, Chairman, President & CEO
Comp: $886.97k
Mr. Ryan M. Confer M.S. (Age 42)
Chief Financial Officer
Comp: $606.57k
Mr. David M. Schloss
Senior Vice President of Human Resources
Mr. Thomas C. Gallagher Esq.
Senior Vice President of Intellectual Property & Licensing
Dr. Mark S. Berger M.D. (Age 69)
Chief Medical Officer
Dr. Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality
Dr. Jack A. Roth F.A.C.S.
M.D., Chairman of Scientific & Medical Advisory Board

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GNPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genprex stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNPX shares.
View GNPX analyst ratings or view top-rated stocks.
What is Genprex's stock price target for 2024?: 1 brokerages have issued 1-year target prices for Genprex's shares. Their GNPX share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 352.5% from the stock's current price.
View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts.
How have GNPX shares performed in 2024?: Genprex's stock was trading at $9.20 at the start of the year. Since then, GNPX stock has decreased by 76.0% and is now trading at $2.21.
View the best growth stocks for 2024 here.
Are investors shorting Genprex?: Genprex saw a decrease in short interest in March. As of March 31st, there was short interest totaling 70,000 shares, a decrease of 12.8% from the March 15th total of 80,300 shares. Based on an average daily trading volume, of 83,200 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.8% of the shares of the stock are sold short.
View Genprex's Short Interest.
When is Genprex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our GNPX earnings forecast.

How were Genprex's earnings last quarter?: Genprex, Inc. (NASDAQ:GNPX) released its quarterly earnings results on Monday, April, 1st. The company reported ($9.20) earnings per share for the quarter, missing analysts' consensus estimates of ($5.40) by $3.80.
When did Genprex's stock split?: Genprex shares reverse split on Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Genprex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).
How do I buy shares of Genprex?: Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNPX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genprex (GNPX) Stock Price, News & Analysis

Genprex MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Genprex Stock (NASDAQ:GNPX)

GNPX Stock Price History

GNPX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

GNPX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™